NCT06328114
Accelerating TMS for Cervical Dystonia
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 23 words
- Secondary endpoints: 3 to 7
- Publications: details revised at 4 of 4 entries
Notable Phase changed: Not applicable → Phase 2v7 Show 5 more changesShow less
- Eligibility criteria expanded, about 125 words
- Trial arms changed: 2 → 3
- Interventions: Transcranial Magnetic Stimulation (TMS) (Device) to Placebo (Drug), Transcranial Magnetic Stimulation (TMS) (Device), trihexyphenidyl 10mg (Drug)
- Secondary endpoints: details revised at 3 of 3 entries
- Study description revised
- Minor Trial status: Recruiting to Enrolling by Invitation
- Site details revised
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jan 2025 to Dec 17, 2024
- Site details revised
- Notable Start date: Jul 1, 2024 to Jan 2025v3
Notable Enrollment target: 20 to 50v2 Show 8 more changesShow less
- Primary endpoints: 2 to 1
- Eligibility criteria shortened, about 2 words
- Study completion date: Jul 1, 2031 to Jul 1, 2029
- Secondary endpoints expanded, about 36 words
- Study description shortened, about 40 words
- Site contact updated
- Study arms: 3 to 2
- Study title shortened, about 4 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Changes in Neck Sensation Measured by Somatosensory Temporal Discrimination Threshold (STDT)
Timeframe: baseline, 12 weeks after each TMS visit.
Secondary (7)
changes in Neck movement dysfluency measured via sensor assays
changes in Neck movement dysfluency measured via sensor assays CMOR
changes in Neck movement dysfluency measured via clinician-rated scales
Changes in Neck movement dysfluency measured via Cervical Dystonia Impact Profile (CDIP-58)- Patient Reported Assessment
Changes in Neck movement dysfluency measured via TWSTR-disability scale- Patient Reported Outcome
Show 2 moreShow less
Changes in Neck movement dysfluency measured via TWSTR-pain scale- Patient Reported Outcome
Changes in Neck movement dysfluency measured via TMS Adverse Events scale- Patient Reported Outcome
Arms and interventions
sham TMSSham comparator
Participants receive sham TMS
TMS to primary somatosensory cortexActive comparator
Participants received TMS sessions at primary somatosensory cortex
TMS to primary somatosensory cortex (Open Label DBS Participants)Active comparator
Participants received TMS sessions at primary somatosensory cortex
Devices: Transcranial Magnetic Stimulation (TMS)
Drugs: Placebo, trihexyphenidyl 10mg
Sites
1 site in 1 country
- Duke University Health SystemDurham, North Carolina, United States